155 related articles for article (PubMed ID: 26700955)
1. Novel Cytochrome P450 Reaction Phenotyping for Low-Clearance Compounds Using the Hepatocyte Relay Method.
Yang X; Atkinson K; Di L
Drug Metab Dispos; 2016 Mar; 44(3):460-5. PubMed ID: 26700955
[TBL] [Abstract][Full Text] [Related]
2. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
[TBL] [Abstract][Full Text] [Related]
3. Reaction Phenotyping of Low-Turnover Compounds in Long-Term Hepatocyte Cultures Through Persistent Selective Inhibition of Cytochromes P450.
Smith S; Lyman M; Ma B; Tweedie D; Menzel K
Drug Metab Dispos; 2021 Nov; 49(11):995-1002. PubMed ID: 34407991
[TBL] [Abstract][Full Text] [Related]
4. In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily.
Usmani KA; Karoly ED; Hodgson E; Rose RL
Drug Metab Dispos; 2004 Mar; 32(3):333-9. PubMed ID: 14977868
[TBL] [Abstract][Full Text] [Related]
5. In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran.
Paris BL; Ogilvie BW; Scheinkoenig JA; Ndikum-Moffor F; Gibson R; Parkinson A
Drug Metab Dispos; 2009 Oct; 37(10):2045-54. PubMed ID: 19608694
[TBL] [Abstract][Full Text] [Related]
6. Assessment of drug-drug interaction for silymarin.
Doehmer J; Tewes B; Klein KU; Gritzko K; Muschick H; Mengs U
Toxicol In Vitro; 2008 Apr; 22(3):610-7. PubMed ID: 18249085
[TBL] [Abstract][Full Text] [Related]
7. In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor.
Hong H; Su H; Ma L; Yao M; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2011 Sep; 39(9):1658-67. PubMed ID: 21673131
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice.
He W; Wu JJ; Ning J; Hou J; Xin H; He YQ; Ge GB; Xu W
Toxicol In Vitro; 2015 Oct; 29(7):1569-76. PubMed ID: 26100226
[TBL] [Abstract][Full Text] [Related]
9. In vitro oxidative metabolism of cajaninstilbene Acid by human liver microsomes and hepatocytes: involvement of cytochrome p450 reaction phenotyping, inhibition, and induction studies.
Hua X; Peng X; Tan S; Li C; Wang W; Luo M; Fu Y; Zu Y; Smyth H
J Agric Food Chem; 2014 Oct; 62(43):10604-14. PubMed ID: 25272989
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of In Vitro Cytochrome P450 Inhibition and In Vitro Fate of Structurally Diverse N-Oxide Metabolites: Case Studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone.
Giri P; Naidu S; Patel N; Patel H; Srinivas NR
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):677-688. PubMed ID: 27853934
[TBL] [Abstract][Full Text] [Related]
11. Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.
Wójcikowski J; Pichard-Garcia L; Maurel P; Daniel WA
Br J Pharmacol; 2003 Apr; 138(8):1465-74. PubMed ID: 12721102
[TBL] [Abstract][Full Text] [Related]
12. LKY-047: First Selective Inhibitor of Cytochrome P450 2J2.
Phuc NM; Wu Z; O Y; Lee JH; Oh S; Song GY; Liu KH
Drug Metab Dispos; 2017 Jul; 45(7):765-769. PubMed ID: 28461575
[TBL] [Abstract][Full Text] [Related]
13. Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation.
Lu C; Suri A; Shyu WC; Prakash S
Biopharm Drug Dispos; 2014 Dec; 35(9):543-52. PubMed ID: 25264242
[TBL] [Abstract][Full Text] [Related]
14. Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450.
Bansal S; Maharao N; Paine MF; Unadkat JD
Drug Metab Dispos; 2020 Oct; 48(10):1008-1017. PubMed ID: 32587099
[TBL] [Abstract][Full Text] [Related]
15. Assessment of multiple cytochrome P450 activities in metabolically inactivated human liver microsomes and roles of P450 2C isoforms in reaction phenotyping studies.
Murayama N; Yajima K; Hikawa M; Shimura K; Ishii Y; Takada M; Uno Y; Utoh M; Iwasaki K; Yamazaki H
Biopharm Drug Dispos; 2018 Feb; 39(2):116-121. PubMed ID: 29136681
[TBL] [Abstract][Full Text] [Related]
16. Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450.
Chen Y; Liu L; Nguyen K; Fretland AJ
Drug Metab Dispos; 2011 Mar; 39(3):373-82. PubMed ID: 21148079
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation.
Weaver R; Graham KS; Beattie IG; Riley RJ
Drug Metab Dispos; 2003 Jul; 31(7):955-66. PubMed ID: 12814974
[TBL] [Abstract][Full Text] [Related]
18. Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes.
Patten CJ; Smith TJ; Murphy SE; Wang MH; Lee J; Tynes RE; Koch P; Yang CS
Arch Biochem Biophys; 1996 Sep; 333(1):127-38. PubMed ID: 8806763
[TBL] [Abstract][Full Text] [Related]
19. An extensive cocktail approach for rapid risk assessment of in vitro CYP450 direct reversible inhibition by xenobiotic exposure.
Spaggiari D; Daali Y; Rudaz S
Toxicol Appl Pharmacol; 2016 Jul; 302():41-51. PubMed ID: 27105555
[TBL] [Abstract][Full Text] [Related]
20. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4.
Spracklin DK; Thummel KE; Kharasch ED
Drug Metab Dispos; 1996 Sep; 24(9):976-83. PubMed ID: 8886607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]